| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-244
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2013-08-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2018-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-104853774-B |
| titleOfInvention |
IL-20 antagonists for the treatment of liver diseases |
| abstract |
Hepatic fibrosis is reduced in a subject having or suspected of having a liver disease with an IL-20 antagonist, which may be an antibody that blocks a signal transduction pathway mediated by IL-20. These antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway. |
| priorityDate |
2012-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |